Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Repligen v. Centocor

  • News

Executive Summary

Repligen settles April 3 lawsuit in exchange for a share of any profits derived from the sale of a potential monoclonal antibody HIV treatment now under development by Centocor. Announced June 9, the settlement allows Centocor to continue work on its F105 antibody while acknowledging a 1987 non-compete agreement with Repligen covering HIV therapeutics, vaccines and diagnostics. That agreement gave Repligen all rights to an AIDS vaccine to which, under an earlier joint venture, Centocor had marketing rights.

Table

View full table

Tags:
Latest Headlines

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

Industry Calls For Caution Over EMA Supply Chain Recommendations

Industry Slates Decision To Exempt Parallel Importers From New Danish Stockpile Rules

Asian Industry Groups Push For Universal Care, E-Labeling, Flexible Supply Chain

See All
UsernamePublicRestriction

Register

PS021036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By